Patents by Inventor Garrison Fathman
Garrison Fathman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11701406Abstract: Provided herein are methods and compositions for treating inflammatory disease by the administration, to a patient in need thereof, of an inhibitor of IL-2R desensitization in combination with a low dose of IL-2. A low dose of interleukin-2 (IL-2) is sufficient to stimulate regulatory T lymphocytes (Tregs) without substantially inducing effector T lymphocytes (Teffs). In some embodiments, the inhibitor of IL-2R desensitization is a small molecule or drug. Is some embodiments the inhibitor is a NEDD8 activating enzyme (NAE) inhibitor. In some embodiments a combination therapy provides for a synergistic effect, where the combination of the inhibitor of IL-2R desensitization and low dose IL-2 provides an effect that is greater than the sum of either the inhibitor or low dose IL-2 administered as a single agent.Type: GrantFiled: May 25, 2018Date of Patent: July 18, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: C. Garrison Fathman, Luis R. Soares
-
Publication number: 20230181306Abstract: The present disclosure provides a method for creating a Biologically Modified Vein Graft with improved survival by pretreating the vein to be used as a vascular graft with compositions comprising oligo-L-arginine, or salts thereof, and an organic acid or a salt thereof. The disclosure further provides methods of improving vascular vein graft survival comprising pretreating the graft for a set period of time with a set concentration of oligo-L-arginines in a buffer comprising either the organic acid or the salt thereof and flushing the BMVG before implantation with the same buffer absent the arginine oligomer. This treatment may prevent vein graft disease in the transplanted vessel.Type: ApplicationFiled: December 9, 2022Publication date: June 15, 2023Inventors: Paul Leo McGrane, C. Garrison Fathman, Jonathan Rothbard
-
Publication number: 20210379155Abstract: Provided herein are methods and compositions for treating inflammatory disease by the administration, to a patient in need thereof, of an inhibitor of IL-2R desensitization in combination with a low dose of IL-2. A low dose of interleukin-2 (IL-2) is sufficient to stimulate regulatory T lymphocytes (Tregs) without substantially inducing effector T lymphocytes (Teffs). In some embodiments, the inhibitor of IL-2R desensitization is a small molecule or drug. Is some embodiments the inhibitor is a NEDD8 activating enzyme (NAE) inhibitor. In some embodiments a combination therapy provides for a synergistic effect, where the combination of the inhibitor of IL-2R desensitization and low dose IL-2 provides an effect that is greater than the sum of either the inhibitor or low dose IL-2 administered as a single agent.Type: ApplicationFiled: May 25, 2018Publication date: December 9, 2021Inventors: C. Garrison Fathman, Luis R. Soares
-
Publication number: 20200246127Abstract: The present disclosure provides a method for creating a Biologically Modified Vein Graft with improved survival by pretreating the vein to be used as a vascular graft with compositions comprising oligo-L-arginine, or salts thereof, and an organic acid or a salt thereof. The disclosure further provides methods of improving vascular vein graft survival comprising pretreating the graft for a set period of time with a set concentration of oligo-L-arginines in a buffer comprising either the organic acid or the salt thereof and flushing the BMVG before implantation with the same buffer absent the arginine oligomer. This treatment may prevent vein graft disease in the transplanted vessel.Type: ApplicationFiled: February 6, 2020Publication date: August 6, 2020Inventors: Paul Leo McGrane, C. Garrison Fathman, Jonathan Rothbard
-
Patent number: 9220744Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.Type: GrantFiled: January 11, 2014Date of Patent: December 29, 2015Assignee: Lumen Therapeutics, LLCInventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
-
Publication number: 20140342986Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.Type: ApplicationFiled: January 11, 2014Publication date: November 20, 2014Applicant: Lumen Therapeutics, LLCInventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
-
Patent number: 8629115Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.Type: GrantFiled: October 20, 2010Date of Patent: January 14, 2014Assignee: Lumen Therapeutics, LLCInventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
-
Patent number: 8513208Abstract: A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-? receptor antagonist, an IFN-? receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.Type: GrantFiled: February 27, 2009Date of Patent: August 20, 2013Assignees: Argos Therapeutics, Inc., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Charles A. Nicolette, C. Garrison Fathman, Remi Creusot
-
Patent number: 7964369Abstract: An active ubiquitin E3 ligase, GRAIL, is crucial in the induction of anergy in cells of the immune system, and in the regulation of cellular proliferation. GRAIL is shown to associate with, and be regulated by Otubain isoforms, including OTUBAIN-1 (DOG, the Destabilizer of GRAIL) and an alternative reading frame splice variant of OTUBAIN-1 (SOG, the Stabilizer of GRAIL). These proteins play opposing roles in the regulation of GRAIL auto-ubiquitination and consequently on its ability to induce anergy and regulate cellular proliferation. DOG serves as an adaptor protein, recruiting the DUB USP8. One major substrate for USP8 is the Ras exchange factor Ras-GRF1, and this protein can be found in a complex with USP8 and GRAIL, which complex is ubiquitinated by GRAIL.Type: GrantFiled: November 9, 2004Date of Patent: June 21, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: C. Garrison Fathman, Luis Soares
-
Publication number: 20110124584Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.Type: ApplicationFiled: October 20, 2010Publication date: May 26, 2011Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
-
Publication number: 20110081327Abstract: A method is provided for treating or preventing an undesired immune response in a patient, comprising: administering to said patient, cells that transiently express, and/or that are transfected with mRNA encoding, one or more polypeptides selected from the group consisting of an IL-4 receptor agonist, an IFN-? receptor antagonist, an IFN-? receptor antagonist, an IL-12 receptor antagonist, an IL-23 receptor antagonist, and a TNF antagonist. Preferably, the cells selectively accumulate in one or more secondary lymphoid tissues at or proximate to the site of the undesired immune response. Related compositions are provided. The methods and compositions are useful for the treatment or prevention of undesired immune responses including, but not limited to, transplant rejection, autoimmune disease, allergy and immune responses directed against therapeutic compositions.Type: ApplicationFiled: February 27, 2009Publication date: April 7, 2011Inventors: Charles A. Nicolette, C. Garrison Fathman, Remi Creuset
-
Patent number: 7820626Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.Type: GrantFiled: October 24, 2008Date of Patent: October 26, 2010Assignee: Lumen Therapeutics, LLCInventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
-
Patent number: 7557087Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.Type: GrantFiled: April 18, 2007Date of Patent: July 7, 2009Assignee: Lumen Therapeutics, LLCInventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
-
Publication number: 20090053283Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.Type: ApplicationFiled: October 24, 2008Publication date: February 26, 2009Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
-
Publication number: 20090012017Abstract: An active ubiquitin E3 ligase, GRAIL, is crucial in the induction of anergy in cells of the immune system, and in the regulation of cellular proliferation. GRAIL is shown to associate with, and be regulated by Otubain isoforms, including OTUBAIN-1 (DOG, the Destabilizer of GRAIL) and an alternative reading frame splice variant of OTUBAIN-1 (SOG, the Stabilizer of GRAIL). These proteins play opposing roles in the regulation of GRAIL auto-ubiquitination and consequently on its ability to induce anergy and regulate cellular proliferation. DOG serves as an adaptor protein, recruiting the DUB USP8. One major substrate for USP8 is the Ras exchange factor Ras-GRF1, and this protein can be found in a complex with USP8 and GRAIL, which complex is ubiquitinated by GRAIL.Type: ApplicationFiled: November 9, 2004Publication date: January 8, 2009Inventors: C. Garrison Fathman, Luis Soares
-
Patent number: 7378089Abstract: Autoimmune disease is treated by the delivery of a suppressive agent to the site of disease. Delivery is accomplished by introducing an expression vector encoding the suppressive agent into cells targeted for such sites, and administering the genetically modified cells to the patient. Suppressive agents of particular interest include IL-4; and anti-CD3 antibodies, particularly single chain anti-CD3 antibodies. Cells of interest for delivery include T cells and T cell hybridomas, where the T cell antigen receptor recognizes epitopes associated with the autoimmune disease. Alternatively, dendritic cells are used as delivery vectors.Type: GrantFiled: October 2, 2002Date of Patent: May 27, 2008Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: C. Garrison Fathman
-
Publication number: 20060167402Abstract: Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.Type: ApplicationFiled: December 20, 2005Publication date: July 27, 2006Inventors: John Cooke, Garrison Fathman, Jonathan Rothbard, Shiro Uemura, Robert Robbins, Murray Kown
-
Publication number: 20060159719Abstract: Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50% of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.Type: ApplicationFiled: December 20, 2005Publication date: July 20, 2006Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John Cooke, Garrison Fathman, Jonathan Rothbard, Shiro Uemura, Robert Robbins, Murray Kown
-
Patent number: 6709840Abstract: Isolated nucleic acid compositions and sequences of anergy associated genes are provided, including the novel GRAIL gene. Expression of these genes is upregulated during the early stages of induction of anergy. The murine GRAIL sequence is shown to attenuate IL-2 transcription in T cells during response to antigenic stimulation. The identification of genes involved in the induction of anergy is useful in the evaluation of the pathophysiology or immunotherapy of cancer, autoimmune disease, and transplant rejection. Genetic sequences involved in anergy induction are useful markers in the evaluation of specific immunotherapies. Functional characterization of genes involved in anergy induction allows the elucidation of the mechanism(s) of T cell anergy, including the transcriptional blockade of IL-2, which may be manipulated to regulate T cell responses in human disease.Type: GrantFiled: May 11, 2001Date of Patent: March 23, 2004Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Gregory Ford, Debra Bloom, C. Garrison Fathman
-
Publication number: 20030091548Abstract: Autoimmune disease is treated by the delivery of a suppressive agent to the site of disease. Delivery is accomplished by introducing an expression vector encoding the suppressive agent into cells targeted for such sites, and administering the genetically modified cells to the patient. Suppressive agents of particular interest include IL-4; and anti-CD3 antibodies, particularly single chain anti-CD3 antibodies. Cells of interest for delivery include T cells and T cell hybridomas, where the T cell antigen receptor recognizes epitopes associated with the autoimmune disease,. Alternatively, dendritic cells are used as delivery vectors.Type: ApplicationFiled: October 2, 2002Publication date: May 15, 2003Inventor: C. Garrison Fathman